Stephen Chan

Stephen has a passion for building efficient data infrastructure for delivering more real-time insights to inform strategic decisions, enhance collaboration, and accelerate advancements that could benefit public health. Stephen’s 25+ years of experience spans multiple therapeutic areas including oncology, infectious diseases, cardiovascular disorders, and CNS. Since joining Revolution Medicines in 2018, he has built a formidable team comprised of the Statistical Programming, Clinical Data Management, and Clinical Systems functions.

Stephen began his oncology journey at the Lawrence Berkeley National Laboratory studying the effects of various growth factors on the branching of epithelial cells in relation to mammary carcinogenesis. From there his biotech and pharmaceutical career advanced with his previous role being Senior Director and Head of Statistical Programming for Acerta Pharma (AstraZeneca subsidiary) where he built and led the programming team to support multiple hematology and solid tumor studies toward the regulatory submission and approval of CALQUENCE® (acalabrutinib). Prior to Acerta Pharma, he played a key role in Pharmacyclics’ initial NDA submission and approval of IMBRUVICA® (ibrutinib). He was also a key contributor to the BEXXAR® (iodine-131 tositumomab) and FluMist® (live attenuated influenza vaccine, intranasal) regulatory submissions and approvals.

Stephen earned his Bachelor’s in Integrative Biology from the University of California at Berkeley.